Commonwealth Equity Services LLC Purchases 3,632 Shares of Stryker Co. (NYSE:SYK)

Commonwealth Equity Services LLC lifted its position in shares of Stryker Co. (NYSE:SYK) by 2.2% in the 4th quarter, Holdings Channel reports. The fund owned 169,527 shares of the medical technology company’s stock after buying an additional 3,632 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Stryker were worth $50,767,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Bremer Bank National Association raised its position in shares of Stryker by 4.0% in the fourth quarter. Bremer Bank National Association now owns 888 shares of the medical technology company’s stock valued at $266,000 after purchasing an additional 34 shares during the period. Simon Quick Advisors LLC lifted its position in shares of Stryker by 3.0% during the fourth quarter. Simon Quick Advisors LLC now owns 1,158 shares of the medical technology company’s stock worth $347,000 after acquiring an additional 34 shares in the last quarter. Consolidated Portfolio Review Corp boosted its holdings in shares of Stryker by 3.6% in the fourth quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company’s stock worth $294,000 after acquiring an additional 34 shares during the period. MBL Wealth LLC raised its stake in shares of Stryker by 4.6% during the 4th quarter. MBL Wealth LLC now owns 850 shares of the medical technology company’s stock valued at $255,000 after purchasing an additional 37 shares during the period. Finally, Cornerstone Planning Group LLC lifted its holdings in Stryker by 30.4% during the 3rd quarter. Cornerstone Planning Group LLC now owns 163 shares of the medical technology company’s stock worth $45,000 after purchasing an additional 38 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 0.6 %

Shares of Stryker stock traded up $1.82 during trading on Friday, reaching $328.45. The company’s stock had a trading volume of 1,589,424 shares, compared to its average volume of 1,415,127. The company has a market cap of $125.12 billion, a price-to-earnings ratio of 37.49, a PEG ratio of 2.55 and a beta of 0.91. The firm’s 50-day moving average is $347.52 and its two-hundred day moving average is $316.85. Stryker Co. has a 52-week low of $249.98 and a 52-week high of $361.41. The company has a quick ratio of 0.97, a current ratio of 1.71 and a debt-to-equity ratio of 0.56.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, topping the consensus estimate of $2.36 by $0.14. Stryker had a return on equity of 23.05% and a net margin of 16.03%. The firm had revenue of $5.24 billion for the quarter, compared to the consensus estimate of $5.10 billion. During the same quarter in the previous year, the business earned $2.14 earnings per share. The company’s quarterly revenue was up 9.7% on a year-over-year basis. On average, sell-side analysts anticipate that Stryker Co. will post 11.94 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 30th. Investors of record on Friday, March 29th were issued a dividend of $0.80 per share. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a yield of 0.97%. Stryker’s dividend payout ratio is currently 36.53%.

Wall Street Analysts Forecast Growth

SYK has been the topic of several analyst reports. Truist Financial upped their price target on Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a research report on Wednesday, January 31st. Piper Sandler increased their target price on shares of Stryker from $375.00 to $380.00 and gave the stock an “overweight” rating in a research note on Wednesday. UBS Group boosted their price target on shares of Stryker from $339.00 to $351.00 and gave the company a “neutral” rating in a research report on Wednesday. Evercore ISI increased their price objective on Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Finally, Needham & Company LLC restated a “hold” rating on shares of Stryker in a research report on Wednesday. Four investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $365.94.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 201,146 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the completion of the transaction, the director now directly owns 3,755,128 shares of the company’s stock, valued at $1,287,633,391.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the transaction, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 201,146 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the completion of the sale, the director now directly owns 3,755,128 shares of the company’s stock, valued at $1,287,633,391.20. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.